留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝硬化门静脉高压相关并发症的防治原则

韦炜 洪依萍

韦炜, 洪依萍. 肝硬化门静脉高压相关并发症的防治原则[J]. 临床肝胆病杂志, 2021, 37(1): 22-25. DOI: 10.3969/j.issn.1001-5256.2021.01.005
引用本文: 韦炜, 洪依萍. 肝硬化门静脉高压相关并发症的防治原则[J]. 临床肝胆病杂志, 2021, 37(1): 22-25. DOI: 10.3969/j.issn.1001-5256.2021.01.005
WEI W, HONG YP. Principles for the prevention and treatment of complications related to cirrhotic portal hy-pertension[J]. J Clin Hepatol, 2021, 37(1): 22-25. DOI: 10.3969/j.issn.1001-5256.2021.01.005
Citation: WEI W, HONG YP. Principles for the prevention and treatment of complications related to cirrhotic portal hy-pertension[J]. J Clin Hepatol, 2021, 37(1): 22-25. DOI: 10.3969/j.issn.1001-5256.2021.01.005

肝硬化门静脉高压相关并发症的防治原则

DOI: 10.3969/j.issn.1001-5256.2021.01.005
详细信息
    作者简介:

    韦炜(1973—),男,主任医师,主要从事消化病肝病学研究

    通讯作者:

    韦炜,jhweiw@163.com

  • 作者贡献声明:韦炜负责拟定写作思路,指导撰写文章并最后定稿; 洪依萍参与文献以及数据等部分资料的收集。
  • 中图分类号: R575.2

Principles for the prevention and treatment of complications related to cirrhotic portal hypertension

  • 摘要: 肝硬化是引起门静脉高压症的最常见原因。门静脉高压症可以引起食管胃静脉曲张、自发性腹膜炎、肝肾综合征以及肝性脑病等并发症,对于门静脉高压规范化诊疗应重视原发病与全程治疗,强调早筛早诊、积极预防、合理救治等链条式全病程管理,对患者制订个体化、精准化管理的预防和治疗方案。
  • [1] Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS); Minimally Invasive Intervention Collaborative Group, Chinese Society of Gastroenterology; Emergency Intervention Committee, Chinese College of Interventionalists, et al. Consensus on clinical application of hepatic venous pressure gradient in China (2018)[J]. J Clin Hepatol, 2018, 34(12): 2526-2536.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.12.008

    中国门静脉高压诊断与监测研究组(CHESS), 中华医学会消化病学分会微创介入协作组, 中国医师协会介入医师分会急诊介入专业委员会, 等. 中国肝静脉压力梯度临床应用专家共识(2018版)[J]. 临床肝胆病杂志, 2018, 34(12): 2526-2536. DOI: 10.3969/j.issn.1001-5256.2018.12.008
    [2] MCDONALD SA, BARCLAY ST, HUTCHINSON SJ, et al. Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: A national database linkage study[J]. Aliment Pharmacol Ther, 2019, 50(4): 425-434. DOI: 10.1111/apt.15320
    [3] Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association.Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portalhy pertension[J]. J Clin Hepatol, 2016, 32(2): 203-219.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2016.02.002

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002
    [4] de FRANCHIS R, Baveno VI Faculty.Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022
    [5] GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis:Risk stratification, diagnosis, and management:2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906
    [6] GROSZMANN RJ, GARCIA-TSAO G, BOSCH J, et al. Beta-blockersto prevent gastroesophageal varices inpatients with cirrhosis[J]. N Engl J Med, 2005, 353(21): 2254-2261. DOI: 10.1056/NEJMoa044456
    [7] TRIPATHl D, STANLEY AJ, HAYES PC, et al. U.K.guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut, 2015, 64(11): 1680-1704. DOI: 10.1136/gutjnl-2015-309262
    [8] VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): A randomised, double-blind, placebo-controlled, multicentretrial[J]. Lancet, 2019, 393(10181): 1597-1608. DOI: 10.1016/S0140-6736(18)31875-0
    [9] SHARMAM, SINGHS, DESAIV, et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: A systematic review and network meta-analysis[J]. Hepatology, 2019, 69(4): 1657-1675. DOI: 10.1002/hep.30220
    [10] ABRALDES JG, VILLANUEVA C, ARACIL C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival inpatientswithcirrhosis[J]. Gastroenterology, 2016, 150(5): 1160-1170. DOI: 10.1053/j.gastro.2016.01.004
    [11] GLUUD LL, KRAG A.Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults[J]. ochrane Database Syst Rev, 2012, (8): CD004544. DOI: 10.1021/cs300439n
    [12] MISHRASR, SHARMABC, KUMARA, et al. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: A randomized controlled trial[J]. J Hepatol, 2011, 54(6): 1161-1167. DOI: 10.1016/j.jhep.2010.09.031
    [13] Cooperation Group for the Survey of Octreotide.Efficacy of octreotide in the treatment of acute variceal bleeding in cirrhotic patients: A prospective, multicentric and randomized clinical trial[J]. Chin J Dig, 2005, 25(1): 37-40.(in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZHHX20050100C.htm

    奥曲肽全国协作组. 两种剂量奥曲肽治疗食管、胃静脉曲张大出血多中心随机对照临床疗效观察[J]. 中华消化杂志, 2005, 25(1): 37-40. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHHX20050100C.htm
    [14] RÖSSLE M. TIPS: 25 years later[J]. J Hepatol, 2013, 59(5): 1081-1093. DOI: 10.1016/j.jhep.2013.06.014
    [15] SUHOCKI PV, LUNGREN MP, KAPOOR B, et al. Transjugular intrahepatic portosystemic shunt complications: Prevention and management[J]. Semin Intervent Radiol, 2015, 32(2): 123-132. DOI: 10.1055/s-0035-1549376
    [16] SIRAMOLPIWAT S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications[J]. World J Gastroenterol, 2014, 20(45): 16996-17010. DOI: 10.3748/wjg.v20.i45.16996
    [17] SINAGRA E, PERRICONE G, D'AMICO M, et al. Systematic review with meta-analysis: The haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J]. Aliment Pharmacol Ther, 2014, 39(6): 557-568. DOI: 10.1111/apt.12634
    [18] FUNAKOSHI N, SÉGALAS-LARGEY F, DUNY Y, et al. Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleeding: A meta-analysis[J]. World J Gastroenterol, 2010, 16(47): 5982-5992. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=99804006&site=ehost-live
    [19] Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association.Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension (2019 edition)[J]. Chin J Dig Surg, 2019, 18(12): 1087-1093.(in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201912001.htm

    中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中华消化外科杂志, 2019, 18(12): 1087-1093. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201912001.htm
    [20] WIEST R, KRAG A, GERBES A. Spontaneous bacterial peritonitis:Recent guidelines and beyond[J]. Gut, 2012, 61(2): 297-310. DOI: 10.1136/gutjnl-2011-300779
    [21] SORT P, NAVASA M, ARROYO V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis[J]. N Engl J Med, 1999, 341(6): 403-409. DOI: 10.1056/NEJM199908053410603
    [22] European Association for the Study of the Liver.EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024
    [23] ANGELI P, GINÈS P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol, 2015, 62(4): 968-974. DOI: 10.1016/j.jhep.2014.12.029
    [24] GLUUD LL, CHRISTENSEN K, CHRISTENSEN E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome[J]. Hepatology, 2010, 51(2): 576-584. DOI: 10.1002/hep.23286
    [25] SCHRIER RW, GROSS P, GHEORGHIADE M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl J Med, 2006, 355(20): 2099-2112. DOI: 10.1056/NEJMoa065181
    [26] BOYER TD, SANYAL AJ, GARCIA-TSAO G, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J]. Liver Transpl, 2011, 17(11): 1328-1332. DOI: 10.1002/lt.22395
    [27] BOSSEN L, KRAG A, VILSTRUP H, et al. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites:Post Hoc analysis of three randomized controlled trials with 1198 patients[J]. Hepatology, 2016, 63(6): 1968-1976. DOI: 10.1002/hep.28352
    [28] European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53(3): 397-417. DOI: 10.1016/j.jhep.2010.05.004
    [29] VILSTRUP H, AMODIO P, BAJAJ J, et al. Hepatic encephalopathy in chronic liver disease:2014 practice guideline by the American Association for the study of liver diseases and the European association for the study of the liver[J]. Hepatology, 2014, 60(2): 715-735. http://smartsearch.nstl.gov.cn/paper_detail.html?id=a143843e7c57d8399c66edd16c8be158
    [30] Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34(10): 2076-2089.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.10.007

    中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34(10): 2076-2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007
    [31] ZHU GQ, SHI KQ, HUANG S, et al. Systematic review with net-work meta-analysis:The comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy[J]. Aliment Phamacol Ther, 2015, 41(7): 624-635. DOI: 10.1111/apt.13122
    [32] QI XL.Full-course management of portal hypertension:Simplicity is the ultimate sophistication[J]. Chin J Hepatol, 2020, 28(9): 721-723.(in Chinese)

    祁小龙. 门静脉高压全病程管理:至繁归于至简[J]. 中华肝脏病杂志, 2020, 28(9): 721-723.
  • 加载中
计量
  • 文章访问数:  182
  • HTML全文浏览量:  38
  • PDF下载量:  67
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-10-10
  • 修回日期:  2020-11-20
  • 刊出日期:  2021-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回